TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00352885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IL-2
Description: IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
Study: NCT02960113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scopolamine patch
Description: Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scopolamine patch
Description: Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupressure point P6
Description: Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupressure point P6
Description: Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
Study: NCT03282487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified release hydrocortisone
Description: Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
Study: NCT00863109

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (PEG)
Description: Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).

Intervention type: DRUG
Intervention: Ribavirin (RBV)
Description: Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
Study: NCT01437696

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: No liquid cholecalciferol will be added to the food.
Study: NCT00702845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa (Org 36286)
Description: 100 µg corifollitropin alfa subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recFSH (follitropin beta)
Description: 150 IU recFSH SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
Description: GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
Description: GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorion gonadatropin (hCG)
Description: hCG 5,000 IU or 10,000 IU administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorion gonadatropin (hCG)
Description: hCG 5,000 IU or 10,000 IU administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: progesterone
Description: Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo-recFSH (follitropin alfa)
Description: Placebo-recFSH administered at the equivalent volume of 150 IU/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo-corifollitropin alfa
Description: Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: open-label recFSH
Description: Open-label recFSH administered up to a maximum dose of 200 IU/day.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: open-label recFSH
Description: Open-label recFSH administered up to a maximum dose of 200 IU/day.
Study: NCT00682565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452 24mg and 6 mg iv infusion
Description: I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452 12.5mg capsule
Description: 12.5mg oral immediate release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452 48 mg and 11 mg iv infusion
Description: I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452 25mg capsule
Description: 25mg oral immediate release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo iv infusion
Description: Matching placebo iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo iv infusion
Description: Matching placebo iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo oral immediate release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo oral immediate release capsule
Study: NCT03513510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iChoose
Study: NCT04094896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCHP
Description: Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCHP
Description: Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
Study: NCT02039726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: 20 or 30 mg quizartinib tablets administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Chemotherapy
Description: Low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA) administered during 28-day cycles
Study: NCT01504256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel
Description: Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil, leucovorin, oxaliplatin, docetaxel
Description: FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)
Study: NCT04013516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Incentive
Description: During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Incentive
Description: During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Call
Description: A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Call
Description: A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Call
Description: A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
Study: NCT01729156

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 1000 mg metformin twice daily in 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg metformin twice daily in 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets twice daily in 3 months
Study: NCT00577850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate
Description: 0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
Study: NCT03538379

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bleeding Control Basic (B-Con) Course
Description: The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bleeding Control Basic (B-Con) Course
Description: The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bleeding Control Basic (B-Con) Course
Description: The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bleeding Control Basic (B-Con) Course
Description: The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bleeding Control Basic (B-Con) Course
Description: The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.
Study: NCT02882919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Yourself v2.0
Description: In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
Study: NCT04147026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinnoTest®
Description: The selection of the biotherapy is carried out based on the recommendations of SinnoTest®. This test categorizes the bDMARDs based on the probability of response. It will allow to prescribe both original molecules, as well as biosimilars, in an equivalent way.~In the SinnoTest® arm, the investigator prescribes the treatment defined as the most effective by SinnoTest®, except in case of contraindication. If contraindicated, the investigator prescribes the second-choice treatment (if any) of SinnoTest® in terms of efficacy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biotherapy prescription without SinnoTest® software
Description: The rheumatologist will use the current guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient
Study: NCT01572701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MIP-1404
Description: 20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
Study: NCT03919981

Intervention type: OTHER
Intervention: Blood sampling
Description: 25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
Study: NCT04603664

Intervention type: DIAGNOSTIC_TEST
Intervention: serum NGAL and cystatin c
Description: measuring serum NGAL and cystatin c on admission and after 48 hours in critically ill patients with covid 19 then compare results to serum creatinine and signs of acute kidney injury
Study: NCT03970551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Counter-maneuver
Description: Physical counter-maneuver targeted at minimizing the large drop in BP seen in IOH patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Counter-maneuver
Description: Physical counter-maneuver targeted at minimizing the large drop in BP seen in IOH patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Test
Description: Stress test involving submerging your hand in ice water or performing mental arithmetic to increase sympathetic activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Test
Description: Stress test involving submerging your hand in ice water or performing mental arithmetic to increase sympathetic activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: A mild electrical stimulus to passively induce a leg muscle contraction with minimal sympathetic activation.
Study: NCT00863863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 125 mg/5 mL Suspension, single dose
Description: A: Experimental Subjects received Alpharma formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grifulvin V® 125 mg/5 mL Suspension, single dose
Description: B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
Study: NCT02693613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kremezin®
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kremezin®
Description: Oral
Study: NCT00551109

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, oral administration, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA4503 Low
Description: Low dose, oral administration, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA4503 High
Description: High dose, oral administration, once daily for 8 weeks
Study: NCT03581201

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory measurements
Description: Laboratory measurements will be collected every week during the Duration of one menstrual cycle and includes the following:~* Hormone analysis~* Clinical chemistry~* Complete blood count~* Adipokines~* Glucose and HbA1c-levels~* Urinary Chemistry

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory measurements
Description: Laboratory measurements will be collected every week during the Duration of one menstrual cycle and includes the following:~* Hormone analysis~* Clinical chemistry~* Complete blood count~* Adipokines~* Glucose and HbA1c-levels~* Urinary Chemistry

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool samples
Description: For a Duration of one menstrual cycle the study participants will be instructed to collect stool samples every two days. The investigation of the intestinal microbiome will be done by sequencing the 16S rRNA gene.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool samples
Description: For a Duration of one menstrual cycle the study participants will be instructed to collect stool samples every two days. The investigation of the intestinal microbiome will be done by sequencing the 16S rRNA gene.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance analysis
Description: The Bioimpedance analysis (BIA) is used for the measurement of body composition and will be done at every study visit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance analysis
Description: The Bioimpedance analysis (BIA) is used for the measurement of body composition and will be done at every study visit.